Nice_老虎社区_美港股上老虎

SebZz
2021-12-02

Nice

Novartis Says Top Drugs Should Fuel Sales Growth Through 2026<blockquote>诺华表示顶级药物应在2026年之前推动销售增长</blockquote>

Novartis AG said Thursday ahead of its research-and-development day starting later today that it exp

Novartis Says Top Drugs Should Fuel Sales Growth Through 2026<blockquote>诺华表示顶级药物应在2026年之前推动销售增长</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":603567349,"tweetId":"603567349","gmtCreate":1638429661733,"gmtModify":1638429661852,"author":{"id":3571302905057300,"idStr":"3571302905057300","authorId":3571302905057300,"authorIdStr":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Nice</p></body></html>","htmlText":"<html><head></head><body><p>Nice</p></body></html>","text":"Nice","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/603567349","repostId":1159695915,"repostType":4,"repost":{"id":"1159695915","kind":"news","pubTimestamp":1638429346,"share":"https://www.laohu8.com/m/news/1159695915?lang=zh_CN&edition=full","pubTime":"2021-12-02 15:15","market":"us","language":"en","title":"Novartis Says Top Drugs Should Fuel Sales Growth Through 2026<blockquote>诺华表示顶级药物应在2026年之前推动销售增长</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1159695915","media":"Marketwatch","summary":"Novartis AG said Thursday ahead of its research-and-development day starting later today that it exp","content":"<p>Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while several new assets could be approved by 2026.</p><p><blockquote>诺华公司周四在今天晚些时候开始的研发日之前表示，预计销售额将在中期保持增长，这主要归功于其主要的市场内增长动力，同时到2026年可能会批准几项新资产。</blockquote></p><p> The Swiss pharma giant said that sales should continue to rise at a compound annual growth rate of at least 4% through 2026, driven by multi-billion dollar sales from its medicines Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio.</p><p><blockquote>这家瑞士制药巨头表示，在其药物Cosentyx、Entresto、Kesimpta、Zolgensma、Kisqali和Leqvio数十亿美元销售额的推动下，到2026年，销售额应继续以至少4%的复合年增长率增长。</blockquote></p><p> \"Up to 20 new assets with significant sales potential could be approved by 2026, which will fuel the next phase of growth and address major unmet needs,\" Novartis's Chief Executive Vas Narasimhan said.</p><p><blockquote>诺华首席执行官Vas Narasimhan表示：“到2026年，可能会批准多达20项具有巨大销售潜力的新资产，这将推动下一阶段的增长并解决主要未满足的需求。”</blockquote></p><p> Novartis also said that Cosentyx, its largest drug by sales, met primary efficacy endpoints in two phase 3 studies called Sunrise and Sunshine in which patients are treated for moderate to severe hidradenitis suppurativa--a chronic skin disease.</p><p><blockquote>诺华还表示，其销售额最大的药物Cosentyx在两项名为Sunrise和Sunshine的3期研究中达到了主要疗效终点，在这些研究中，患者接受了中度至重度化脓性汗腺炎（一种慢性皮肤病）的治疗。</blockquote></p><p></p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Says Top Drugs Should Fuel Sales Growth Through 2026<blockquote>诺华表示顶级药物应在2026年之前推动销售增长</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Says Top Drugs Should Fuel Sales Growth Through 2026<blockquote>诺华表示顶级药物应在2026年之前推动销售增长</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Marketwatch</strong><span class=\"h-time small\">2021-12-02 15:15</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while several new assets could be approved by 2026.</p><p><blockquote>诺华公司周四在今天晚些时候开始的研发日之前表示，预计销售额将在中期保持增长，这主要归功于其主要的市场内增长动力，同时到2026年可能会批准几项新资产。</blockquote></p><p> The Swiss pharma giant said that sales should continue to rise at a compound annual growth rate of at least 4% through 2026, driven by multi-billion dollar sales from its medicines Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio.</p><p><blockquote>这家瑞士制药巨头表示，在其药物Cosentyx、Entresto、Kesimpta、Zolgensma、Kisqali和Leqvio数十亿美元销售额的推动下，到2026年，销售额应继续以至少4%的复合年增长率增长。</blockquote></p><p> \"Up to 20 new assets with significant sales potential could be approved by 2026, which will fuel the next phase of growth and address major unmet needs,\" Novartis's Chief Executive Vas Narasimhan said.</p><p><blockquote>诺华首席执行官Vas Narasimhan表示：“到2026年，可能会批准多达20项具有巨大销售潜力的新资产，这将推动下一阶段的增长并解决主要未满足的需求。”</blockquote></p><p> Novartis also said that Cosentyx, its largest drug by sales, met primary efficacy endpoints in two phase 3 studies called Sunrise and Sunshine in which patients are treated for moderate to severe hidradenitis suppurativa--a chronic skin disease.</p><p><blockquote>诺华还表示，其销售额最大的药物Cosentyx在两项名为Sunrise和Sunshine的3期研究中达到了主要疗效终点，在这些研究中，患者接受了中度至重度化脓性汗腺炎（一种慢性皮肤病）的治疗。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click\">Marketwatch</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华"},"source_url":"https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1159695915","content_text":"Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while several new assets could be approved by 2026.\nThe Swiss pharma giant said that sales should continue to rise at a compound annual growth rate of at least 4% through 2026, driven by multi-billion dollar sales from its medicines Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio.\n\"Up to 20 new assets with significant sales potential could be approved by 2026, which will fuel the next phase of growth and address major unmet needs,\" Novartis's Chief Executive Vas Narasimhan said.\nNovartis also said that Cosentyx, its largest drug by sales, met primary efficacy endpoints in two phase 3 studies called Sunrise and Sunshine in which patients are treated for moderate to severe hidradenitis suppurativa--a chronic skin disease.","news_type":1,"symbols_score_info":{"NVS":0.9}},"isVote":1,"tweetType":1,"viewCount":2402,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}